The relatively higher percentage of women enrolled in the GN trials likely reflect the high proportion of lupus nephritis trials which enrolled a majority of female patients, reflecting the higher prevalence of disease in women than men (85% women).23 In addition, many IgA trials were conducted in Asia where the prevalence of disease is high in women—for example, the ratio of men to women in biopsy-proven IgA in Asia is 2:1 in contrast to Northern Europe and the United States where the ratio is 6:1.24 Indeed, the region of enrollment seemed to be important more broadly. The gene discussed is CD79A; the disease is lupus nephritis.